Previous 10 | Next 10 |
Compugen's COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Activity in Triple Immunotherapy Combination in Patients with Recurrent Metastatic MSS Endometrial Cancer PR Newswire COM701 in combination with nivolumab and BMS-986207 (anti-TIGIT) resulted in encoura...
2023-05-15 14:21:02 ET Compugen Ltd. (CGEN) Q1 2023 Earnings Conference Call May 15, 2023 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Alberto Se...
Compugen Reports First Quarter 2023 Results PR Newswire On track to deliver initial findings from studies with the triple blockade of PVRIG, TIGIT and PD-1 in patients with MSS CRC and platinum resistant ovarian cancer by end of 2023 New pre-clinical data presented at CIMT...
2023-05-12 14:27:16 ET Compugen ( NASDAQ: CGEN ) is scheduled to announce Q1 earnings results on Monday, May 15th, before market open. The consensus EPS Estimate is -$0.11 Over the last 3 months, EPS estimates have seen 2 upward revisions and 0 downward. For ...
Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tuesday, May 23, 2023 PR Newswire HOLON, Israel , May 11, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer i...
Compugen to Present at the JMP Securities Life Sciences Conference PR Newswire HOLON, Israel , May 9, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery...
Compugen to Release First Quarter 2023 Results on Monday, May 15, 2023 PR Newswire HOLON, Israel , May 1, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discov...
Compugen to Present New Clinical Data Showing Preliminary Anti-Tumor Activity of COM701 Triple Combination in Recurrent MSS-Metastatic Endometrial Cancer at ASCO 2023 PR Newswire HOLON, Israel , April 27, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TAS...
Compugen to Present Data on its Lead Pre-Clinical Asset COM503 in an Oral Presentation at the 20th CIMT Annual Meeting PR Newswire COM503 a potential first-in-class, high affinity anti- IL18 binding protein antibody frees endogenous IL-18 to inhibit cancer growth Compugen ...
2023-03-13 08:46:21 ET Capstone Green Energy ( NASDAQ: CGEN ) announced that its authorized distributor in Alaska, Arctic Energy, received new orders from two leading oil and gas operators. The first order is for a C600S microturbine to power a major oil and gas ...
News, Short Squeeze, Breakout and More Instantly...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...